Establishment Labs Holdings Inc. Price & Performance (ESTA)

Recent filings reveal that major institutions, including Brown Advisory and Capital Research, have significantly increased their holdings in Establishment Labs. While the company faces profitability challenges, analysts remain moderately optimistic, with a consensus rating of 'Moderate Buy' and a price target averaging $57.40—suggesting potential upside despite recent share volatility.12

Needham has initiated coverage of Establishment Labs with a Hold recommendation, citing the anticipated U.S. launch of Motiva implants as a key growth driver. Despite a sharp stock decline over the past year, analysts see room for improvement, though international market headwinds and recent earnings misses temper optimism.34

Analysts project an average one-year price target of $56.68 for Establishment Labs, reflecting an 86% potential upside from recent levels. Forecasts highlight robust expected revenue growth, though the company continues to operate at a loss. The outlook underscores both the risks and opportunities facing the medtech firm.53